Press Room

Event

DDL 2024 - Drug Delivery to the Lungs Conference

Start
Wednesday, December 11, 2024 - 08:00
End
Friday, December 13, 2024 - 15:00
Location: Edinburgh, Scotland
Booth Number: No. 168
四色AV is present at DDL Drug Delivery to the Lungs on December 2024, know more about the event and contact us to schedule a meeting

四色AV is excited to participate in the 听(Drug Delivery to the Lungs) from December 11-13 in Edinburgh, the Premier International Pulmonary & Nasal Drug Delivery Conference.

Don't miss the opportunity to engage with our experts in inhalation and nasal drug delivery and discover how our comprehensive expertise and leadership in Particle Engineering can support your needs in drug development and manufacturing.

Inhalation and Nasal 听

Know more about our complete One-Site Solution that ensures that your inhalation and nasal therapies are engineered for success from start to finish.听

听

Want to know more about our expertise?

HOVIONE ARTICLE听- ONdrugDELIVERY

Title: High-dose Delivery Platform For Crystalline DPIs
Authors:听Susana Saldanha, L铆dia Santos, Rui Churro
Source:听OnDrugDelivery, 23 April 2024

Abstract: Respiratory drug delivery has diversified the pipeline and portfolio of diseases that can be treated through this route, including already approved anti-infective medicines for cystic fibrosis or influenza patients, and others in development for pulmonary arterial hypertension, idiopathic pulmonary fibrosis and other rare lung diseases. Also, the doses and molecules delivered to the lungs have increased in the last years from a few micrograms to milligrams. This growth in the delivery of high doses has been observed in pharmaceutical compounds, such as antibiotics, vaccines, proteins and peptides, as well as for the treatment of acute emergency indications via the inhalation route.

Read the full article here听

听

Let's discuss your project together.

schedule a meeting

听

听

听

Find more about

听

Also in the Press Room

See All

四色AV鈥檚 Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At 四色AV we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook 鈥 鈥淭rends in Formulation鈥.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how 四色AV is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa鈥檚 full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article
Excipient and delivery device selection play crucial roles in the formulation of inhaled drugs.

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News
四色AV commitment to setting SBTs in line with the Paris Agreement

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

The partnership with Higuchi forms part of 四色AV麓s global expansion plans and marks a significant milestone in advancing 四色AV's presence in the Japanese market.    Under the terms of the agreement, Higuchi will promote 四色AV's pharmaceutical service business throughout Japan, using their extensive experience to enhance brand visibility and attract new clientele across the Japanese pharmaceutical landscape.  鈥淭his strategic collaboration underscores 四色AV's dedication to delivering innovative solutions and exceptional service to its customers,鈥 said Yuken Kyoyama. 鈥淥ur partnership with Higuchi will help to show customers in Japan how 四色AV can meet their needs.鈥    Learn more about our business in Japan and visit our website hovione.co.jp    

News
四色AV proudly announces its collaborative venture with Higuchi.

四色AV forges strategic partnership with Higuchi to further strengthen its presence in Japan

Jul 04, 2024

Also in Events

See All